Diamyd Medical AB (fra:DMN) Share Price

Company Profile

Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWE
T: +46 86610026
https://www.diamyd.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2026
Employees
45

Recommended

We’re expecting another beat-and-raise quarter, while watching the roadmap and discussions of its financing and partnership deals.

Brian Colello, CPA | 24 August 2026

Profits flatten as airport ramps up redevelopment.

Angus Hewitt, CFA | 24 August 2026

Income appeal backed by growth projects.

Adrian Atkins | 24 August 2026

Index	Last price	Change	% Change
All Ordinaries	9,316.70	9.20	0.10%
CAC 40	8,465.40	19.03	-0.22%
DAX 40	26,117.59	18.97	-0.07%
Dow JONES (US)	53,277.01	517.80	0.98%
FTSE 100	10,818.56	2.00	0.02%
HKSE	25,517.33	492.13	-1.89%
NASDAQ	26,180.46	113.29	0.43%
Nikkei 225	65,528.09	488.27	-0.74%
NZX 50 Index	13,881.88	90.78	-0.65%
S&P 500	7,674.37	33.21	0.43%
S&P/ASX 200	9,103.10	9.90	0.11%
SSE Composite Index	3,882.01	23.19	-0.59%